PMS-LORAZEPAM 0.5 MG
LORAZEPAM : 0.5 MG · DIN 00728187 · PHARMASCIENCE INC
Health Canada status: MARKETED
What is PMS-LORAZEPAM?
PMS-LORAZEPAM 0.5 MG contains LORAZEPAM : 0.5 MG. It is listed in the Health Canada Drug Product Database under DIN 00728187, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 31-Dec-1988. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-LORAZEPAM used for?
Short-term relief of manifestations of excessive anxiety in patients with anxiety neurosis; adjunct for relief of excessive anxiety prior to surgical interventions.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00728187 |
|---|---|
| Brand name | PMS-LORAZEPAM |
| Generic / active ingredient | LORAZEPAM : 0.5 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 0.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05BA06 LORAZEPAM |
| AHFS class | 28:24.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1988 |
| Original market date | 1988-12-31 00:00:00 |
How is it administered?
Individualize dosage. Generalized Anxiety: 2-3 mg/day in divided doses (max 6 mg/day). Geriatric/debilitated: reduce initial dose by 50%. Taper gradually to discontinue.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 mentioned but content not visible), though standard benzodiazepine security is advised.
How is it supplied?
0.5 mg: Bottles of 100, 500, 1,000. 1 mg: Bottles of 100, 500, 1,000, 3,000. 2 mg: Bottles of 100, 500, 1,000.
Contraindications
Myasthenia gravis, acute narrow angle glaucoma, known hypersensitivity to benzodiazepines or any ingredient in the formulation.
Warnings and precautions
Risk of addiction, abuse, misuse, and life-threatening withdrawal. Concomitant use with opioids may cause fatal respiratory depression. Risk of falls/fractures. Not for psychotic/depressed patients.
Is LORAZEPAM in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N05BA06 LORAZEPAM. 17 of 53 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LORAZEPAM | 0.5 MG | TABLET | APOTEX INC | MARKETED | DIN 00655740 |
| APO-LORAZEPAM | 1 MG | TABLET | APOTEX INC | MARKETED | DIN 00655759 |
| APO-LORAZEPAM | 2 MG | TABLET | APOTEX INC | MARKETED | DIN 00655767 |
| LORAZEPAM INJECTION USP | 4 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02243278 |
| LORAZEPAM INJECTION, USP | 4 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02550962 |
| LORAZEPAM SUBLINGUAL | 0.5 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02410745 |
| LORAZEPAM SUBLINGUAL | 1 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02410753 |
| LORAZEPAM SUBLINGUAL | 2 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02410761 |
| PMS-LORAZEPAM | 1 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 00728195 |
| PMS-LORAZEPAM | 2 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 00728209 |
Who else supplies LORAZEPAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LORAZEPAM appears in 67 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.